Book contents
- Next Generation Antidepressants
- Next Generation Antidepressants
- Copyright page
- Contents
- Contributors
- Preface
- Abbreviations
- Chapter 1 Current depression landscape
- Chapter 2 Novel therapeutic targets for treating affective disorders
- Chapter 3 Developing novel animal models of depression
- Chapter 4 Translational research in mood disorders
- Chapter 5 Defining depression endophenotypes
- Chapter 6 Genetic and genomic studies of major depressive disorder
- Chapter 7 Medicinal chemistry challenges in the design of next generation antidepressants
- Chapter 8 Application of pharmacogenomics and personalized medicine for the care of depression
- Index
- References
Chapter 8 - Application of pharmacogenomics and personalized medicine for the care of depression
Published online by Cambridge University Press: 19 October 2021
- Next Generation Antidepressants
- Next Generation Antidepressants
- Copyright page
- Contents
- Contributors
- Preface
- Abbreviations
- Chapter 1 Current depression landscape
- Chapter 2 Novel therapeutic targets for treating affective disorders
- Chapter 3 Developing novel animal models of depression
- Chapter 4 Translational research in mood disorders
- Chapter 5 Defining depression endophenotypes
- Chapter 6 Genetic and genomic studies of major depressive disorder
- Chapter 7 Medicinal chemistry challenges in the design of next generation antidepressants
- Chapter 8 Application of pharmacogenomics and personalized medicine for the care of depression
- Index
- References
Summary
Remarkable progress notwithstanding, pharmacotherapy for depressive and related conditions, as well as pharmacological intervention of various other psychiatric and medical conditions, has typically ignored the magnitude and clinical relevance of the huge inter-individual variations in pharmacokinetics and pharmacodynamics. Such neglects lead to additional risks of severe and/or unpleasant side effects, medication non-adherence, prolonged periods of titration, suboptimal therapeutic responses, and treatment failures. Advances in pharmacogenomics and computer modeling technologies hold promises for achieving the goals of “personalized” (“individualized”) medicine. However, challenges abound for realizing such goals, including the packaging and interpretation of genotyping results, ethical considerations, financing, economy of scale, inertia against changes in medical practice (innovation diffusion), as well as other infrastructural and organizational issues related to the use of new information.
- Type
- Chapter
- Information
- Next Generation AntidepressantsMoving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders, pp. 119 - 131Publisher: Cambridge University PressPrint publication year: 2010